Terms: = Thyroid cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Clinical Outcome
3 results:
1. Genetic landscape of papillary thyroid carcinoma in the Chinese population.
Liang J; Cai W; Feng D; Teng H; Mao F; Jiang Y; Hu S; Li X; Zhang Y; Liu B; Sun ZS
J Pathol; 2018 Feb; 244(2):215-226. PubMed ID: 29144541
[TBL] [Abstract] [Full Text] [Related]
2. fas ligand (fasL, apo-1L/cd95L) expression and clinical outcome in papillary microcarcinoma and papillary thyroid carcinomas with diameter smaller than 1.5 centimeters.
Bayraktaroglu T; Boztepe H; Kapran Y; Tanakol R; Alagöl F
Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):537-43. PubMed ID: 20013612
[TBL] [Abstract] [Full Text] [Related]
3. High prevalence of c-RET expression in papillary thyroid carcinomas from the Korean population.
Lee S; Hong SW; Moon WC; Oh MR; Lee JK; Ahn CW; Cha BS; Kim KR; Lee HC; Lim SK
Thyroid; 2005 Mar; 15(3):259-66. PubMed ID: 15785245
[TBL] [Abstract] [Full Text] [Related]
